10:03 AM EST - Labopharm Inc. : and Paladin Labs Inc. announced today that they have entered into a definitive agreement pursuant to which Paladin will acquire all of the issued and outstanding common shares of Labopharm at a price of $0.2857 per share in cash, which represents a premium of 57.4% over the volume-weighted average price of Labopharm's shares of $0.1815 for the 30 trading days prior to this announcement. Labopharm Inc.
shares T.DDS are trading up $0.11 at $0.28.
